{"result": "(\"entity\"<|>CASTAÑO I<|>PERSON<|>Castaño I is one of the authors referenced in the clinical impact study of pituitary adenomas.)\n##\n(\"entity\"<|>MARTÍNEZ DE LA PISCINA I<|>PERSON<|>Martínez de la Piscina I is one of the authors referenced in the clinical impact study of pituitary adenomas.)\n##\n(\"entity\"<|>PORTILLO N<|>PERSON<|>Portillo N is one of the authors referenced in the clinical impact study of pituitary adenomas.)\n##\n(\"entity\"<|>RICA I<|>PERSON<|>Rica I is one of the authors referenced in the clinical impact study of pituitary adenomas.)\n##\n(\"entity\"<|>CORDIDO F<|>PERSON<|>Cordido F is one of the authors of the practical guide for the diagnosis and treatment of acromegaly.)\n##\n(\"entity\"<|>GARCÍA ARNÉS JA<|>PERSON<|>García Arnés JA is one of the authors of the practical guide for the diagnosis and treatment of acromegaly.)\n##\n(\"entity\"<|>MARAZUELA ASPIROZ M<|>PERSON<|>Marazuela Aspiroz M is one of the authors of the practical guide for the diagnosis and treatment of acromegaly.)\n##\n(\"entity\"<|>TORRES VELA E<|>PERSON<|>Torres Vela E is one of the authors of the practical guide for the diagnosis and treatment of acromegaly.)\n##\n(\"entity\"<|>KATZNELSON L<|>PERSON<|>Katznelson L is one of the authors of the clinical practice guideline for acromegaly.)\n##\n(\"entity\"<|>LAWS ER JR<|>PERSON<|>Laws ER Jr is one of the authors of the clinical practice guideline for acromegaly.)\n##\n(\"entity\"<|>MELMED S<|>PERSON<|>Melmed S is one of the authors of the clinical practice guideline for acromegaly.)\n##\n(\"entity\"<|>MOLITCH ME<|>PERSON<|>Molitch ME is one of the authors of the clinical practice guideline for acromegaly.)\n##\n(\"entity\"<|>MURAD MH<|>PERSON<|>Murad MH is one of the authors of the clinical practice guideline for acromegaly.)\n##\n(\"entity\"<|>UTZ A<|>PERSON<|>Utz A is one of the authors of the clinical practice guideline for acromegaly.)\n##\n(\"entity\"<|>WASS JA<|>PERSON<|>Wass JA is one of the authors of the clinical practice guideline for acromegaly.)\n##\n(\"entity\"<|>SOCIETY ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Society of Endocrinology and Nutrition in Spain is involved in the development of clinical guidelines for acromegaly.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a medical resource that provides clinical information, including treatment guidelines for acromegaly.)\n##\n(\"entity\"<|>ACROMEGALY<|>EVENT<|>Acromegaly is a hormonal disorder that results from excess growth hormone, leading to enlarged bones and tissues.)\n##\n(\"relationship\"<|>CASTAÑO I<|>ACROMEGALY<|>Castaño I contributed to the research on the clinical impact of findings related to acromegaly.<|>7)\n##\n(\"relationship\"<|>MARTÍNEZ DE LA PISCINA I<|>ACROMEGALY<|>Martínez de la Piscina I contributed to the research on the clinical impact of findings related to acromegaly.<|>7)\n##\n(\"relationship\"<|>PORTILLO N<|>ACROMEGALY<|>Portillo N contributed to the research on the clinical impact of findings related to acromegaly.<|>7)\n##\n(\"relationship\"<|>RICA I<|>ACROMEGALY<|>Rica I contributed to the research on the clinical impact of findings related to acromegaly.<|>7)\n##\n(\"relationship\"<|>CORDIDO F<|>ACROMEGALY<|>Cordido F is involved in the practical guide for the diagnosis and treatment of acromegaly.<|>8)\n##\n(\"relationship\"<|>GARCÍA ARNÉS JA<|>ACROMEGALY<|>García Arnés JA is involved in the practical guide for the diagnosis and treatment of acromegaly.<|>8)\n##\n(\"relationship\"<|>MARAZUELA ASPIROZ M<|>ACROMEGALY<|>Marazuela Aspiroz M is involved in the practical guide for the diagnosis and treatment of acromegaly.<|>8)\n##\n(\"relationship\"<|>TORRES VELA E<|>ACROMEGALY<|>Torres Vela E is involved in the practical guide for the diagnosis and treatment of acromegaly.<|>8)\n##\n(\"relationship\"<|>KATZNELSON L<|>ACROMEGALY<|>Katznelson L is involved in the clinical practice guideline for acromegaly.<|>9)\n##\n(\"relationship\"<|>LAWS ER JR<|>ACROMEGALY<|>Laws ER Jr is involved in the clinical practice guideline for acromegaly.<|>9)\n##\n(\"relationship\"<|>MELMED S<|>ACROMEGALY<|>Melmed S is involved in the clinical practice guideline for acromegaly.<|>9)\n##\n(\"relationship\"<|>MOLITCH ME<|>ACROMEGALY<|>Molitch ME is involved in the clinical practice guideline for acromegaly.<|>9)\n##\n(\"relationship\"<|>MURAD MH<|>ACROMEGALY<|>Murad MH is involved in the clinical practice guideline for acromegaly.<|>9)\n##\n(\"relationship\"<|>UTZ A<|>ACROMEGALY<|>Utz A is involved in the clinical practice guideline for acromegaly.<|>9)\n##\n(\"relationship\"<|>WASS JA<|>ACROMEGALY<|>Wass JA is involved in the clinical practice guideline for acromegaly.<|>9)\n##\n(\"relationship\"<|>SOCIETY ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ACROMEGALY<|>The Society of Endocrinology and Nutrition in Spain provides guidelines for the diagnosis and treatment of acromegaly.<|>8)\n##\n(\"relationship\"<|>UPTODATE INC<|>ACROMEGALY<|>UpToDate Inc. provides clinical information and guidelines for the treatment of acromegaly.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: nicos: ancianos y mujeres en edad fértil tienen mejor respuesta que los varones y jóvenes.\n- Tamaño tumoral: tumores más pequeños y menos invasivos tienen mejor respuesta que los grandes e invasivos.\n- Concentraciones de GH e IGF-1 pretratamiento: peor pronóstico cuanto mayor es la cifra de GH e IGF-1.\n- Test agudo de octreotida: la buena respuesta al test sugiere buena respuesta a los análogos.\n- Pruebas de imagen: la captación en el octreoscan y la señal hipointensa en T2 en la RMN predicen buena respuesta, mientras que los hiperintensos en T2 responden peor.\n- Realización de cirugía o radioterapia previa: es factor de mejor pronóstico.\n- Histología: los tumores densamente granulados se asocian a mejor respuesta que los escasamente granulados.\n\n## Predictores moleculares:\n\nA nivel molecular, destacan como predictores de mala respuesta a análogos de somatostatina:\n\n- Disminución de SSTR2.\n- SSTR2/SSTR5 < 1,3.\n- SSTR5TMD4+ (variante truncada de SSTR5).\n- Disminución de ZAC1.\n- Disminución de E-cadherina.\n- Mutación en AIP.\n- Aumento de Ki-67.\n- Aumento de p53.\n- Aumento de PTTG.\n- Disminución de p27.\n- Disminución de MGMT.\n\nLa presencia del oncogen gsp (mutación en la subunidad del complejo Gsα) es por el contrario un factor de buena respuesta.\n\nReferencias:\n- Castaño I, Martínez de la Piscina I, Portillo N, Rica I. Adenomas hipofisarios: Impacto clínico de los hallazgos moleculares. Rev Esp Endocrinol Pediatr. 2017;8(Suppl):35-45.\n- Cordido F, García Arnés JA, Marazuela Aspiroz M, Torres Vela E; grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición. Guía práctica de diagnóstico y tratamiento de la acromegalia. Endocrinol Nutr. 2013;60(8):457.e1.\n- Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(11):3933-51.\n- Melmed S, Katznelson L. Treatment of acromegaly. En: Snyder PJ, Martin KA, eds. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 29 de abril de 2019).\n\n## 1.9 Diabetes insípida\n\n| 53 | Paciente con poliuria y polidipsia que presenta los siguientes resultados en el test de la sed: osmolaridad urinaria 700 mOsm/kg y tras la administración de desmopresina 710 mOsm/kg. Indique el diagnóstico más probable: |\n|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|    | A. Diabetes insípida central parcial.                                                                                                                                                                                                               |\n|    | B. Secreción inadecuada de hormona antidiurética.                                                                                                                                                                                                   |\n|    | C. Diabetes insípida nefrogénica.                                                                                                                                                                                                                   |\n|    | D. Polidipsia primaria.                                                                                                                                                                                                                             |\n\n### COMENTARIO\n\nEl test de la sed, también denominado de la deshidratación o de Miller, es una prueba indicada en el diagnóstico diferencial de la poliuria acuosa. Se basa en el hecho de que, en condiciones normales, la privación de agua provoca deshidratación y eleva la tonicidad plasmática. Esto constituye un estímulo para la liberación de ADH y concentra la orina, tanto en sujetos sanos como en aquellos con polidipsia primaria. Sin embargo, la concentración de la orina no ocurre en pacientes con diabetes insípida, ya sea central o nefrogénica.\n\nLa duración de la prueba es variable, con un máximo de 17 h, o se interrumpe antes cuando se producen las siguientes situaciones:\n\n- Osmolaridad urinaria > 600-800 mOsm/kg o densidad urinaria >1.020.\n- Estabilización de la osmolaridad urinaria (plateau): variación menor de 30 mOsm/kg en dos determinaciones.\n- Pérdida superior al 3-5% del peso basal.\n- Sed intolerable o hipovolemia.\n- Osmolalidad plasmática > 295-300 mOsm/kg o sodio plasmático >145-148 mEq/l.\n\nTras finalizar la deshidratación se realiza la prueba de desmopresina, administrando entre 2 y 4 µg subcutáneos del fármaco, para diferenciar la diabetes insípida central de la nefrogénica. Requiere haber alcanzado el máximo estímulo de ADH endógen\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}